Question 1

How was eptifibatide discovered from snake venom?

Accepted Answer

Eptifibatide was developed from barbourin, a disintegrin protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). Many snake venoms contain disintegrin proteins that prevent blood clotting to keep prey bleeding. Barbourin was unusual because it contained a KGD (Lys-Gly-Asp) sequence rather than the typical RGD (Arg-Gly-Asp) found in most disintegrins. Scientists at the University of Mississippi and Millennium Pharmaceuticals (later Schering-Plough) synthesized a small cyclic peptide containing this KGD motif, creating eptifibatide — a potent, selective GP IIb/IIIa inhibitor suitable for clinical use.

Question 2

How does eptifibatide compare to abciximab and tirofiban?

Accepted Answer

All three are intravenous GP IIb/IIIa inhibitors, but they differ significantly. Abciximab (ReoPro) is a humanized monoclonal antibody fragment with irreversible binding, a long biological half-life (hours to days), and the highest bleeding risk. Eptifibatide (Integrilin) is a cyclic peptide with reversible binding and a 2.5-hour half-life. Tirofiban (Aggrastat) is a non-peptide small molecule with reversible binding and a similar half-life. Eptifibatide and tirofiban are preferred over abciximab in most current practice due to their reversibility and more predictable pharmacokinetics. Abciximab use has largely been supplanted.

Question 3

When is eptifibatide contraindicated?

Accepted Answer

Eptifibatide is contraindicated in patients with active internal bleeding or history of bleeding within the prior 30 days; recent (within 6 weeks) major surgery or severe trauma; history of hemorrhagic stroke or any stroke within 30 days; severe uncontrolled hypertension (SBP >200 or DBP >110 mmHg); platelet count <100,000/μL; severe renal impairment (CrCl <10 mL/min or dialysis); and concurrent use of another GP IIb/IIIa inhibitor. Caution is warranted with concomitant anticoagulant therapy and in patients over 75 years of age.

Question 4

Is GP IIb/IIIa inhibitor use declining?

Accepted Answer

Yes. GP IIb/IIIa inhibitor use has declined substantially over the past decade due to several factors: routine use of potent oral P2Y12 inhibitors (prasugrel, ticagrelor) that provide sustained platelet inhibition; the shift to radial artery access for PCI, which dramatically reduces bleeding; bivalirudin monotherapy strategies that achieve good outcomes without GP IIb/IIIa inhibitors; and evidence that pre-treatment with GP IIb/IIIa inhibitors before angiography does not improve outcomes. Current guidelines recommend eptifibatide primarily as bailout therapy for thrombotic complications during PCI.

Route	Dosage Range	Frequency	Notes
Intravenous bolus + infusion (ACS — FDA-approved)	180 mcg/kg IV bolus, then 2 mcg/kg/min continuous infusion	Up to 72 hours or until hospital discharge	Indicated for ACS (unstable angina/NSTEMI) managed medically or with PCI. Reduce infusion to 1 mcg/kg/min if CrCl <50 mL/min. Contraindicated if CrCl <10 mL/min or on dialysis.
Intravenous bolus + infusion (PCI — FDA-approved)	180 mcg/kg IV bolus immediately before PCI, second 180 mcg/kg bolus 10 minutes later, then 2 mcg/kg/min infusion	Infusion continued for 18-24 hours post-PCI	Double-bolus regimen for PCI achieves higher, more sustained receptor occupancy. Used with concomitant heparin (target ACT 200-300 seconds). Aspirin and clopidogrel should be administered per ACS guidelines.

Eptifibatide

Key Facts

Benefits

Dosage Protocols

Side Effects

Frequently Asked Questions

References

Latest Research